Trillium Asset Management LLC Boosts Stock Position in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Trillium Asset Management LLC grew its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 13.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,687 shares of the medical instruments supplier's stock after buying an additional 12,813 shares during the period. Trillium Asset Management LLC owned 0.19% of Merit Medical Systems worth $8,407,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in MMSI. Valued Wealth Advisors LLC acquired a new stake in Merit Medical Systems during the fourth quarter worth approximately $29,000. Tompkins Financial Corp acquired a new stake in Merit Medical Systems during the fourth quarter worth approximately $38,000. Headlands Technologies LLC bought a new position in Merit Medical Systems in the third quarter worth approximately $41,000. DekaBank Deutsche Girozentrale bought a new position in Merit Medical Systems in the third quarter worth approximately $67,000. Finally, Quadrant Capital Group LLC boosted its holdings in Merit Medical Systems by 60.7% in the fourth quarter. Quadrant Capital Group LLC now owns 2,126 shares of the medical instruments supplier's stock worth $161,000 after acquiring an additional 803 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MMSI. Barrington Research increased their price target on Merit Medical Systems from $98.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, May 1st. Oppenheimer increased their price target on Merit Medical Systems from $82.00 to $87.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. Canaccord Genuity Group cut their price target on Merit Medical Systems from $112.00 to $102.00 and set a "buy" rating on the stock in a report on Wednesday, May 1st. Raymond James increased their price target on Merit Medical Systems from $84.00 to $89.00 and gave the stock an "outperform" rating in a report on Tuesday, January 30th. Finally, StockNews.com upgraded Merit Medical Systems from a "hold" rating to a "buy" rating in a report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.78.

Insiders Place Their Bets

In other Merit Medical Systems news, CFO Raul Jr. Parra sold 6,480 shares of the firm's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $73.95, for a total value of $479,196.00. Following the completion of the sale, the chief financial officer now directly owns 12,007 shares of the company's stock, valued at $887,917.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Merit Medical Systems news, CFO Raul Jr. Parra sold 6,480 shares of the firm's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $73.95, for a total value of $479,196.00. Following the completion of the sale, the chief financial officer now directly owns 12,007 shares of the company's stock, valued at $887,917.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Wright sold 25,000 shares of Merit Medical Systems stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $75.68, for a total value of $1,892,000.00. Following the completion of the transaction, the insider now owns 42,223 shares of the company's stock, valued at $3,195,436.64. The disclosure for this sale can be found here. Insiders sold 49,637 shares of company stock valued at $3,751,673 over the last ninety days. 3.70% of the stock is currently owned by insiders.

Merit Medical Systems Stock Performance

Merit Medical Systems stock traded down $0.37 during mid-day trading on Friday, reaching $81.89. 287,535 shares of the company's stock were exchanged, compared to its average volume of 388,571. The business's fifty day simple moving average is $75.01 and its 200 day simple moving average is $75.26. The firm has a market capitalization of $4.76 billion, a PE ratio of 47.06, a P/E/G ratio of 2.29 and a beta of 0.91. Merit Medical Systems, Inc. has a one year low of $62.58 and a one year high of $85.62. The company has a quick ratio of 4.38, a current ratio of 6.03 and a debt-to-equity ratio of 0.65.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its quarterly earnings results on Tuesday, April 30th. The medical instruments supplier reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.71 by $0.06. Merit Medical Systems had a return on equity of 15.02% and a net margin of 7.94%. The business had revenue of $323.51 million for the quarter, compared to analyst estimates of $315.57 million. During the same period last year, the company posted $0.64 earnings per share. Merit Medical Systems's quarterly revenue was up 8.7% compared to the same quarter last year. On average, sell-side analysts expect that Merit Medical Systems, Inc. will post 3.33 earnings per share for the current year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.